Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2021-05-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Microbiota Transplantation for Decompensated Cirrhosis
NCT03014505
Faecal Microbiota Transplantation for Liver Cirrhosis
NCT04932577
Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease
NCT03648086
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
NCT06533852
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
NCT02721264
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fecal microbiota transplantation
The fecal bacteria were transplanted once every 5 days for a total of 4 times.
fecal microbiota transplantation
The fecal bacteria were transplanted once every 5 days for a total of 4 times
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fecal microbiota transplantation
The fecal bacteria were transplanted once every 5 days for a total of 4 times
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18-65
* According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol / L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)
Exclusion Criteria
* Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc
* Patients with liver cancer, lung cancer, lymphoma and other malignant tumors
* Patients taking anticoagulants, mental diseases and immune diseases for a long time
* Pregnant or lactating women.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xulanman
Head of Infection Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ningbo Medical Center Lihuili Hospital,Affiliated Lihuili hospital of Ningbo University
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KJ2019PJ021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.